Minnesota data analytics IDs potential savings

The Minnesota Department of Health (MDH) has analyzed the state’s emergency department visits, hospital admissions and hospital readmissions and found that over the course of a year nearly 1.3 million of those patient visits costing nearly $2 billion were potentially preventable.  

MDH used 2012 claims data from the Minnesota All Payer Claims Database (MN APCD) and data analytics developed by Minnesota’s 3M Company to estimate the volume of potentially preventable patient visits to hospitals and emergency departments, according to a release.  Minnesota is the first state in the nation to successfully conduct such an analysis using APCD data and set a baseline estimate for potentially preventable hospital visits.

“Minnesota has one of the most efficient and cost-effective healthcare systems in the nation but this study shows we still have room for improvement,” said Minnesota Commissioner of Health Ed Ehlinger, MD, MSPH. “Equipped with these findings, we will work with providers and community leaders to ensure patients more consistently receive the right care, in the right place at the right time.”

Nearly 50,000 events were potentially preventable hospital admissions totaling $373 million. The top three conditions for potentially preventable admissions included: pneumonia, excluding pneumonia related to bronchiolitis and respiratory syncytial virus (13 percent), heart failure (12.1 percent), and COPD (8.1 percent).

About 22,000 hospital readmissions costing $237 million were found to be potentially preventable. For readmissions, the three most frequent conditions account for approximately 15.2 percent of all readmissions and include heart failure (6.6 percent), blood infection (septicemia) and disseminated infection (5.1 percent), and major depressive disorder and other unspecified psychoses (3.5 percent).

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.